Trial Profile
Safety and efficacy of glecaprevir/pibrentasvir combination therapy for hepatitis C infected patients with chronic hepatitis or liver cirrhosis
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Feb 2021
Price :
$35
*
At a glance
- Drugs Glecaprevir/pibrentasvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 02 Feb 2018 New trial record